Stroke Emergency Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Stroke is a sudden interruption of blood supply to part of the brain, causing rapid death of brain cells and consequent neurological deficits. It is the second leading cause of death globally and the leading cause of acquired disability in adults, with approximately 13.7 million new strokes occurring each year worldwide. Strokes are classified as ischaemic (caused by a blood clot blocking a cerebral artery, accounting for 85–87% of strokes) or haemorrhagic (caused by rupture of a blood vessel within or around the brain — 13–15%). Ischaemic stroke is subdivided by mechanism: large artery atherosclerotic occlusion, cardioembolic (from a cardiac source such as atrial fibrillation, valvular disease, or myocardial infarction), small vessel (lacunar) disease, and undetermined cause (cryptogenic).

The public stroke recognition campaign FAST — Face drooping (unilateral facial droop, asymmetric smile), Arm weakness (one arm drifting down when raised), Speech difficulty (slurred, confused, or absent), Time to call emergency services — achieves early stroke recognition by the lay public and has been instrumental in reducing treatment delays. More comprehensive clinical tools used by healthcare professionals include the National Institutes of Health Stroke Scale (NIHSS), which quantifies stroke severity across 15 domains of neurological function and guides treatment decisions. A score of 1–4 indicates minor stroke, 5–15 moderate, 16–20 moderate-to-severe, and above 21 severe stroke.

The core principle of stroke emergency treatment is captured in the phrase 'time is brain' — every minute of large artery occlusion causes death of approximately 1.9 million neurons. The modern stroke pathway compresses the time from symptom onset to reperfusion therapy to the absolute minimum: pre-hospital FAST recognition and immediate 999/112/911 activation, ambulance pre-notification of the receiving hospital, immediate brain imaging on arrival (CT without contrast to exclude haemorrhage, followed by CT angiography to identify large vessel occlusion), and rapid administration of IV thrombolysis and/or mechanical thrombectomy for eligible patients.

Stroke emergency treatment addresses both acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH). Acute ischaemic stroke presents with sudden onset neurological deficit — most commonly facial droop, arm or leg weakness (hemiparesis or hemiplegia), dysphasia (difficulty producing or understanding language), dysarthria, homonymous hemianopia (half visual field loss), or vertigo and ataxia (posterior circulation stroke). Large vessel occlusion (LVO) — occlusion of the internal carotid artery, middle cerebral artery, basilar artery, or proximal posterior cerebral artery — affects approximately 30% of ischaemic strokes and causes the most devastating deficits, but also responds to mechanical thrombectomy.

Transient ischaemic attack (TIA) — a stroke-like episode that resolves completely within 24 hours (often much faster, within minutes) without infarction on MRI — is a neurological emergency requiring immediate treatment because the 48-hour risk of major stroke following TIA is 10–20% without urgent intervention. The ABCD2 score and ABCD3-I score stratify TIA patients by short-term stroke risk and guide the urgency of investigation and initiation of antiplatelet therapy, anticoagulation (for cardioembolic cause), carotid imaging, and echocardiography. Intracerebral haemorrhage is managed by blood pressure control, reversal of anticoagulation if present, avoidance of secondary haemorrhage expansion, and in selected cases neurosurgical intervention for cerebellar haematomas, hydrocephalus, or superficial lobar haematomas.

Intravenous alteplase (tPA — tissue plasminogen activator) thrombolysis is approved for ischaemic stroke patients presenting within 4.5 hours of symptom onset (the onset-to-needle time) without contraindications. Contraindications include haemorrhage on CT scan, recent surgery within 14 days, prior intracranial haemorrhage, blood pressure above 185/110 mmHg not controlled by IV antihypertensives, active bleeding, blood glucose below 3 mmol/L or above 22 mmol/L (as these may mimic stroke), and anticoagulant use with therapeutic anticoagulation levels. The benefit-to-risk ratio of thrombolysis is highest in more severe strokes and when treatment is delivered earliest — the number needed to treat (NNT) for a good outcome is 8–10 when given within 90 minutes.

Mechanical thrombectomy — endovascular removal of the clot using a stent retriever or aspiration catheter — is indicated for patients with LVO (large vessel occlusion) ischaemic stroke within 6 hours of symptom onset with an NIHSS score of 6 or above and evidence of salvageable brain tissue (penumbra) on advanced imaging. The DAWN and DEFUSE-3 trials extended the thrombectomy window to 24 hours for carefully selected patients with favourable penumbral imaging. Thrombectomy is performed in comprehensive stroke centres with 24-hour neurointerventional radiology capability.

Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, 10% as IV bolus and 90% as infusion over 60 minutes) remains the most widely available reperfusion treatment and is indicated for eligible patients across all hospital levels with imaging capability. Tenecteplase (a single-bolus fibrinolytic with higher fibrin specificity) has demonstrated non-inferiority to alteplase in clinical trials and is increasingly used as a more convenient alternative, particularly when patients require rapid transfer for thrombectomy after thrombolysis.

Mechanical thrombectomy represents the most dramatic advance in stroke treatment since thrombolysis. Five landmark trials published in 2015 (MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, THRACE) simultaneously demonstrated overwhelming efficacy of mechanical thrombectomy for LVO ischaemic stroke, with a 40–50% relative risk reduction in death or major disability and NNT for functional independence of 3–4. Modern thrombectomy uses stent retrievers (deployed through the thrombus, then retracted with the clot adherent) or direct aspiration catheters (ADAPT technique), with technical success (TICI 2b/3 reperfusion) achieved in 85–90% of cases by experienced neurointerventionalists. Comprehensive stroke centres have specific protocols to minimise door-to-groin puncture time, targeting under 90 minutes. Futile recanalization — restoring blood flow to irreversibly infarcted tissue — does not benefit and may worsen outcomes; advanced CT or MRI perfusion imaging identifies the penumbra (salvageable tissue) and selects patients most likely to benefit.

Mechanical thrombectomy for LVO ischaemic stroke has transformed outcomes for this most severe stroke subtype. Pooled analysis from the 2015 landmark trials demonstrated a 46% absolute increase in functional independence (modified Rankin Scale 0–2) at 90 days in thrombectomy-treated patients versus standard care alone. For every 3–4 patients treated, one additional patient achieves functional independence who would not have done so with medical treatment alone. Mortality at 90 days was reduced by 5% absolute risk reduction. Even patients with baseline severe stroke (NIHSS above 20) benefit substantially — outcomes previously considered inevitably disabling can be dramatically reversed with successful large vessel reperfusion.

Even without thrombectomy, care in a dedicated stroke unit — compared to general medical ward care — reduces death and disability by 18–20% (strong evidence from multiple randomised controlled trials and meta-analyses), representing one of the most robust organisational interventions in medicine. Rapid TIA investigation and treatment (dual antiplatelet therapy, statin, blood pressure management, anticoagulation for atrial fibrillation) initiated urgently in a TIA clinic or stroke unit reduces 90-day stroke risk by approximately 80% compared to delayed treatment — preventing thousands of strokes annually where TIA clinics have been implemented.

Intravenous thrombolysis carries a 2–6% risk of symptomatic intracranial haemorrhage (SICH) — haemorrhagic transformation of the infarct with neurological deterioration — which is life-threatening in approximately half of cases. Other bleeding complications include major systemic haemorrhage (0.4–1%) and minor cutaneous or mucosal bleeding. Despite this risk, the overall balance of benefit versus harm favours thrombolysis for eligible patients, particularly those with moderate to severe deficits, as the risk of death or major disability from the untreated stroke typically far exceeds the haemorrhage risk.

Mechanical thrombectomy procedural complications include groin haematoma or vascular access complications (2–5%), vessel perforation during catheterisation (1–2%), distal embolisation of clot fragments causing new territory infarction, and contrast nephropathy in patients with pre-existing renal impairment. Malignant middle cerebral artery infarction — in which massive MCA territory infarction causes progressive cerebral oedema and herniation — may develop in 10–15% of large stroke patients and requires early decompressive hemicraniectomy (surgical removal of a skull flap) to be life-saving, particularly in patients under 60 years of age. Post-stroke complications include aspiration pneumonia (a leading cause of early post-stroke mortality), urinary tract infection, deep vein thrombosis, and depression (affecting approximately 30% of stroke survivors).

All patients with confirmed stroke should be admitted to a dedicated stroke unit — a geographically defined area with a specialised multidisciplinary stroke team (neurologist/stroke physician, specialist nurses, physiotherapist, occupational therapist, speech and language therapist, dietitian, and social worker) providing coordinated 24-hour stroke-specific nursing and early rehabilitation. Stroke unit care has been one of the most consistently evidence-based organisational advances in stroke medicine, with meta-analysis demonstrating reduced mortality, reduced dependency, and shorter hospital stay.

Stroke rehabilitation begins on the first or second day after stroke and continues in hospital, then in dedicated community stroke rehabilitation services. Physiotherapy targets motor recovery and mobility, occupational therapy targets activities of daily living and return to function, and speech and language therapy addresses dysphasia and dysphagia (swallowing difficulty — present in up to 50% of acute stroke patients and a major aspiration risk). Secondary prevention — antiplatelet therapy (aspirin plus clopidogrel for the first 3 weeks, then monotherapy), anticoagulation for atrial fibrillation (direct oral anticoagulants, initiated 4–14 days post-stroke depending on infarct size), high-intensity statin, blood pressure control, and lifestyle modification — dramatically reduces recurrent stroke risk.

Stroke is one of the most costly conditions in healthcare systems worldwide due to acute care, rehabilitation, and the long-term social care costs of disability. In the United States, the average cost of acute stroke hospitalisation is $15,000–40,000; mechanical thrombectomy adds $25,000–50,000 in procedure and facility costs; total lifetime costs of a disabling stroke may exceed $100,000 including rehabilitation and long-term care. In the UK, total annual NHS stroke costs are estimated at £3.5 billion, with community and social care costs accounting for the largest proportion.

For stroke rehabilitation and long-term neurorehabilitation, significant cost savings are available internationally. Dedicated neurorehabilitation units in India offer comprehensive stroke rehabilitation programmes — physiotherapy, occupational therapy, speech therapy, neuropsychological rehabilitation — at $200–800 per week compared to $5,000–15,000 per week at US inpatient rehabilitation facilities. Thailand, Malaysia, and Turkey offer similar neurorehabilitation services at significant cost advantages. Patients must be medically stable for travel and should continue all secondary prevention medications and have appropriate medical follow-up arranged at the destination hospital.

In the acute stroke emergency context, there are no alternatives to evidence-based emergency stroke care — the treatments described (thrombolysis, thrombectomy, stroke unit care) are life-saving and disability-preventing interventions. Delay in seeking emergency care for stroke symptoms is the most dangerous 'alternative' choice — every hour of delay after symptom onset results in the equivalent of approximately 3.6 years of normal brain ageing from neuron loss.

For secondary stroke prevention — preventing recurrent stroke — the range of interventions is well-defined: carotid endarterectomy (surgical removal of atherosclerotic plaque from the carotid artery) for symptomatic carotid stenosis above 50%, direct oral anticoagulants for atrial fibrillation, blood pressure-lowering therapy (reducing BP by 10/5 mmHg reduces stroke recurrence risk by approximately 30%), high-intensity statin (reduces stroke and cardiovascular events by 20–35%), and lifestyle modification (smoking cessation, Mediterranean diet, regular aerobic exercise, weight management). Aspirin is appropriate for secondary prevention only in specific indications; for atrial fibrillation, anticoagulation is dramatically superior to aspirin.